Kent Lai

List of Publications by Year
in descending order

32 papers	1,006 citations	430874 18 h-index	434195 31 g-index
34 all docs	34 docs citations	34 times ranked	855 citing authors

#	Article	IF	Citations
1	A prevalent mutation for galactosemia among black Americans. Journal of Pediatrics, 1996, 128, 89-95.	1.8	112
2	Galactose toxicity in animals. IUBMB Life, 2009, 61, 1063-1074.	3.4	106
3	Regulation of Inositol Transport in Saccharomyces cerevisiae Involves Inositol-induced Changes in Permease Stability and Endocytic Degradation in the Vacuole. Journal of Biological Chemistry, 1995, 270, 2525-2534.	3.4	77
4	Involvement of endoplasmic reticulum stress in a novel Classic Galactosemia model. Molecular Genetics and Metabolism, 2007, 92, 78-87.	1.1	68
5	Overexpression of Human UDP-Glucose Pyrophosphorylase Rescues Galactose-1-Phosphate Uridyltransferase-Deficient Yeast. Biochemical and Biophysical Research Communications, 2000, 271, 392-400.	2.1	60
6	Intracellular galactose-1-phosphate accumulation leads to environmental stress response in yeast model. Molecular Genetics and Metabolism, 2005, 86, 360-371.	1.1	57
7	Functional Analysis of the Human Galactose-1-Phosphate Uridyltransferase Promoter in Duarte and LA Variant Galactosemia. Molecular Genetics and Metabolism, 2001, 72, 297-305.	1.1	53
8	High-Throughput Screening for Human Galactokinase Inhibitors. Journal of Biomolecular Screening, 2008, 13, 415-423.	2.6	45
9	The Biochemical Role of Glutamine 188 in Human Galactose-1-phosphate Uridyltransferase. Journal of Biological Chemistry, 1999, 274, 6559-6566.	3.4	44
10	Subfertility and growth restriction in a new galactose-1 phosphate uridylyltransferase (GALT) - deficient mouse model. European Journal of Human Genetics, 2014, 22, 1172-1179.	2.8	43
11	The Leloir Pathway of Galactose Metabolism â€“ A Novel Therapeutic Target for Hepatocellular Carcinoma. Anticancer Research, 2016, 36, 6265-6272.	1.1	41
12	Novel mRNA-Based Therapy Reduces Toxic Galactose Metabolites and Overcomes Galactose Sensitivity in a Mouse Model of Classic Galactosemia. Molecular Therapy, 2020, 28, 304-312.	8.2	38
13	Structure-Function Analyses of a Common Mutation in Blacks with Transferase-Deficiency Galactosemia. Molecular Genetics and Metabolism, 2001, 74, 264-272.	1.1	33
14	Galactose-1 phosphate uridylyltransferase (GalT) gene: A novel positive regulator of the PI3K/Akt signaling pathway in mouse fibroblasts. Biochemical and Biophysical Research Communications, 2016, 470, 205-212.	2.1	28
15	Correlation assessment among clinical phenotypes, expression analysis and molecular modeling of 14 novel variations in the human galactose-1-phosphate uridylyltransferase gene. Human Mutation, 2012, 33, 1107-1115.	2.5	25
16	GALK inhibitors for classic galactosemia. Future Medicinal Chemistry, 2014, 6, 1003-1015.	2.3	24
17	Structure activity relationships of human galactokinase inhibitors. Bioorganic and Medicinal Chemistry Letters, 2015, 25, 721-727.	2.2	20
18	Structureâ€“Activity Analysis and Cell-Based Optimization of Human Galactokinase Inhibitors. ACS Medicinal Chemistry Letters, 2011, 2, 667-672.	2.8	19

#	Article	IF	Citations
19	Alternative pathways of galactose assimilation: could inverse metabolic engineering provide an alternative to galactosemic patients?. Metabolic Engineering, 2004, 6, 239-244.	7.0	17
20	Black children deficient in galactose 1-phosphate uridyltransferase: Correlation of activity and immunoreactive protein in erythrocytes and leukocytes. Journal of Pediatrics, 1997, 130, 972-980.	1.8	16
21	Discovery of novel inhibitors of human galactokinase by virtual screening. Journal of Computer-Aided Molecular Design, 2019, 33, 405-417.	2.9	14
22	A novel phosphoglucomutaseâ€deficient mouse model reveals aberrant glycosylation and early embryonic lethality. Journal of Inherited Metabolic Disease, 2019, 42, 998-1007.	3.6	13
23	Integrated stress response control of granulosa cell translation and proliferation during normal ovarian follicle development. Molecular Human Reproduction, 2021, 27, .	2.8	11
24	Discovery of Novel Inhibitors Targeting Multi-UDP-hexose Pyrophosphorylases as Anticancer Agents. Molecules, 2020, 25, 645.	3.8	9
25	Assessment of ataxia phenotype in a new mouse model of galactoseâ€1 phosphate uridylyltransferase (GALT) deficiency. Journal of Inherited Metabolic Disease, 2017, 40, 131-137.	3.6	8
26	Effect of genotype on galactose-1-phosphate in classic galactosemia patients. Molecular Genetics and Metabolism, 2018, 125, 258-265.	1.1	7
27	Fragment Screening Reveals Starting Points for Rational Design of Galactokinase 1 Inhibitors to Treat Classic Galactosemia. ACS Chemical Biology, 2021, 16, 586-595.	3.4	6
28	Formal synthesis of 4-diphosphocytidyl-2-C-methyl d-erythritol from d-(+)-arabitol. Tetrahedron, 2012, 68, 8937-8941.	1.9	3
29	The Galactose Index measured in fibroblasts of GALT deficient patients distinguishes variant patients detected by newborn screening from patients with classical phenotypes. Molecular Genetics and Metabolism, 2020, 129, 171-176.	1.1	3
30	Pathophysiology and management of classic galactosemic primary ovarian insufficiency. Reproduction and Fertility, 2021, 2, R67-R84.	1.8	3
31	Structure-Based Optimization of Small Molecule Human Galactokinase Inhibitors. Journal of Medicinal Chemistry, 2021, 64, 13551-13571.	6.4	2
32	Prevalence of epithelial abnormalities and high-risk human papilloma virus in cervicovaginal Pap smears of population subgroups as a guide toward evidence-based best practice. Diagnostic Cytopathology, 2019, 47, 648-652.	1.0	1